tbuckley/cabot-search huggingface dataset:
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Authors: Ajay K Nooka, Andrew J. Yee, Carol Ann Huff, Dan T. Vogl, Maria Gavriatopoulou, Ajai Chari, Philippe Moreau, David Dingli, Craig E. Cole, Sagar Lonial, Meletios A. Dimopoulos, Joshua R Richter, Ravi Vij, Sascha A Tuchman, Marc S Raab, Noa Biran, David S. Siegel, Paul G. Richardson, Jianjun Liu, Anita Joshi, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Sundar Jagannath
Journal: Blood (2019)
SURG-09. CHANGING PARADIGMS IN THE MANAGEMENT OF CEREBRAL METASTASES
Authors: Edvin Telemi, James Snyder, Ian Lee, Adam Robin
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Paradigms in the management of cerebral metastases (CM) are evolving, in part due to the expanded use of laser interstitial thermal therapy or LITT in lesion ablation, with treatment of CM comprising up to 34% of all LITT cases. Currently, CM are treated with LITT largely in the setting of disease progression after initial therapy with focused radiation with no standard for performing biopsy prior to LITT. In this study we aim to assess the significance of the pathology of the lesion at the time of LITT on survival. METHODS We conducted a retrospective review of our institution’s LITT/brain tumor database and identified patients who underwent LITT with concurrent biopsy. For deceased patients, we identified cause of death if secondary to neurologic causes defined as death either due to direct intracranial disease progression leading to rapid neurologic decline or due to progressive neurologic decline without significant extracranial disease burden. RESULTS We identified 16 progressive CM lesions in 15 adults treated with LITT with concurrent biopsy, predominantly with non-small cell lung cancer. The mean age at LITT was 62, median follow-up was 8.5 months and thirteen of fifteen patients had previous focused radiation therapy. Eleven of sixteen lesions demonstrated radiation necrosis(RN) without tumor and 5 with tumor progression(TP). The mean survival in patients with RN was 548 days compared with 285 days in patients with TP (p=0.15). Of the 9 deceased, 2 of 5 patients with RN and 3 of 4 patients with TP died of neurologic causes. CONCLUSIONS Although statistically not significant due to the small sample size, this preliminary analysis suggests that clinically significant differences in survival and cause of death may exist between patients with RN and TP. Further evaluation with implications for treatment, prognosis and the expectant management of the patient with CM is warranted.
Echocardiography Parameters Predicting Postoperative Atrial Fibrillation: their Influence on Early left Atrial Remodelling and Right Ventricular Function after Heart Valve Surgery
Authors: Yolanda Carrascal
Journal: Clinical Cardiology and Cardiovascular Interventions (2019)

Objective: To identify relationship between echocardiographic parameters variations and risk of postoperative atrial fibrillation (POAF) after cardiac valve surgery.Design: Prospective.Case-control study.Setting: A university hospital. Participants:We analysed the incidence of POAF in 90 patients undergoing elective heart valve surgery.POAF was considered when episodes equal or longer than 5 minutes, and those under 5 minutes with hemodynamic disturbances.Interventions: None.Measurements and main results: POAF incidence was 36.7%.Preoperative echocardiographic study showed higher systolic pulmonary pressure (p: 0.047) and longer atrial electromechanical interval (AEI) (0.049) in POAF group.Postoperative echocardiographic evaluation revealed higher TAPSE decreasing related with preoperative values (8.18± 4.33 mm in No-POAF vs. 10.35 ± 3.83 mm in POAF group) (p: 0.026).In multivariate logistic regression POAF correlated with age> 65 years (p: 0.007) OR: 4.80; IC 95% (1.52-15.14),longer preoperative AEI (p: 0.042) OR: 1.029 IC 95% (1.001-1.059),higher TAPSE reduction (p: 0.040) OR: 1.15 IC 95% (1.006-1.316)and postoperative left atrial volume index> 36 ml / m2 (p = 0.0203) OR: 3.63; 95% CI (1.23-11.92).Conclusions: After heart valve surgery, POAF favoured right ventricular dysfunction (evidenced by higher postoperative TAPSE decreasing) and impaired early left atrial remodelling.In older patients and those with preoperative longer AEI, biatrial pacing and pharmacological prophylaxis might prevent these undesirable POAF effects.
Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients
Authors: Shuhua Yi, Wenjie Xiong, Yi Wang, Rui Lv, Li Zengjun, Wei Liu, Tingyu Wang, An Gang, Shuhui Deng, Yan Xu, Weiwei Sui, Dehui Zou, Lugui Qiu
Journal: Blood (2019)
2019 American Heart Association Focused Update on Neonatal Resuscitation: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
Authors: Marilyn B. Escobedo, Khalid Aziz, Vishal S. Kapadia, Henry C. Lee, Susan Niermeyer, Georg M. Schmölzer, Edgardo Szyld, Gary M. Weiner, Myra H. Wyckoff, Nicole K. Yamada, Jeanette G. Zaichkin
Journal: Circulation (2019)

This 2019 focused update to the American Heart Association neonatal resuscitation guidelines is based on 2 evidence reviews recently completed under the direction of the International Liaison Committee on Resuscitation Neonatal Life Support Task Force. The International Liaison Committee on Resuscitation Expert Systematic Reviewer and content experts performed comprehensive reviews of the scientific literature on the appropriate initial oxygen concentration for use during neonatal resuscitation in 2 groups: term and late-preterm newborns (≥35 weeks of gestation) and preterm newborns (<35 weeks of gestation). This article summarizes those evidence reviews and presents recommendations. The recommendations for neonatal resuscitation are as follows: In term and late-preterm newborns (≥35 weeks of gestation) receiving respiratory support at birth, the initial use of 21% oxygen is reasonable. One hundred percent oxygen should not be used to initiate resuscitation because it is associated with excess mortality. In preterm newborns (<35 weeks of gestation) receiving respiratory support at birth, it may be reasonable to begin with 21% to 30% oxygen and to base subsequent oxygen titration on oxygen saturation targets. These guidelines require no change in the Neonatal Resuscitation Algorithm-2015 Update.
EDIT-301: An Experimental Autologous Cell Therapy Comprising Cas12a-RNP Modified mPB-CD34+ Cells for the Potential Treatment of SCD
Authors: Edouard De Dreuzy, Jack Heath, John A Zuris, Patricia Sousa, Ramya Viswanathan, Sean Scott, Jen Da Silva, Terence Ta, Stacy Capehart, Tongyao Wang, Cecilia Fernandez, Vic E Myer, Charles F Albright, Christopher J Wilson, Sandra Teixeira, Kai-Hsin Chang
Journal: Blood (2019)
EXTH-04. BLOCKADE OF NRF2/GLUTATHIONE METABOLISM AS A SYNTHETIC LETHALITY APPROACH FOR IDH1-MUTATED GLIOMA
Authors: Yang Liu, Yanxin Lu, Orieta Celiku, Aiguo Li, Chunzhang Yang
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Mutations in isocitrate dehydrogenase (IDH1/2) are frequent genetic abnormalities in human malignancies. IDH1/2-mutated cancers are a recently defined disease entity with distinctive patterns of tumor cell biology, metabolism and resistance to therapy. Molecular targeting approaches against this disease cluster remain limited. METHODS We investigated the redox homeostasis in IDH1 mutant-transduced cells and patient-derived brain tumor initiating cells. The importance of antioxidant genes was confirmed through COX regression analysis on a large cohort of lower grade glioma. We investigated the biologic impact of Nuclear factor erythroid 2-related factor 2 (NRF2) on the glutathione de novo synthesis in IDH1-mutated cells. Finally, we evaluated the value of targeting NRF2/glutathione metabolic pathway as a potential synthetic lethality approach for IDH1-mutated cell in vitro and in vivo. RESULTS We discovered that acquisition of cancer-associated IDH1 mutants results in constitutive activation of NRF2-governed cytoprotective pathways through decoupling of NRF2 from its E3 ligase Kelch-like ECH-associated protein 1. NRF2 mediated the transcriptional activation of GCLC, GCLM and SLC7A11, which strengthens the glutathione de novo synthesis, and relieves the metabolic burden derived from IDH1 mutant neomorphic activity. Blockade of the NRF2/glutathione metabolic pathway synergizes with the elevated intrinsic reactive oxygen species, which results in overwhelming oxidative damage in IDH1-mutated cells, as well as a substantial reduction in tumor cell proliferation and xenograft expansion. CONCLUSION Our findings suggest that blockade of the NRF2/glutathione synthetic pathway is a novel targeting strategy for IDH1-mutated malignancies.
Tumor Origins Through Genomic Profiles
Authors: Edison T. Liu, Susan M. Mockus
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis
Authors: Sneha Purvey, Kenneth Seier, Sean M. Devlin, Josel D Ruiz, Molly A. Maloy, Gunjan L. Shah, Hani Hassoun, Sergio A. Giralt, Heather J Landau
Journal: Blood (2019)
Outcomes of Therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem Cell Transplantation - Twenty-Year Experience from a Tertiary Care Center
Authors: RAM V Nampoothiri, Arjun Law, Wilson Lam, Zeyad Al-Shaibani, David Loach, Carol Chen, Dennis Dong Hwan Kim, Fotios V. Michelis, Rajat Kumar, Jonas Mattsson, Jeffrey H. Lipton, Auro Viswabandya
Journal: Blood (2019)
Pensions crisis: Make extra hours non-pensionable to ease winter pressure, says NHS Confederation
Authors: Gareth Iacobucci
Journal: BMJ (2019)

The government should consider allowing any pay from extra hours worked by senior doctors to be non-pensionable if they exceed their full-time contracts, to ease workforce pressures this winter, the body that represents NHS organisations has recommended.

In a letter to the chancellor, Sajid Javid, the NHS Confederation’s chief executive, Niall Dickson, urged the Treasury to consider the “time-limited” measure to minimise delays, cancellations, and disruptions to services this winter.1

A tapered annual allowance introduced in 2016 places a limit on how much senior staff can put into their pension pots and causes a tax charge if this is exceeded.

The NHS Confederation and the BMA …
Therapeutic implications of MTH1 inhibitor TH1579 in cutaneous malignant melanoma
Authors: I. Das, H. Gad, L. Bräutigam, L. Pudelko, R. Tuominen, V. Höiom, I. Almlöf, J. Hansson, T. Helleday, S.E. Brage, U.W. Berglund
Journal: Annals of Oncology (2019)
Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients
Authors: Loic Ysebaert, Anne-Sophie Michallet, Fontanet Bijou, Aline Clavert, Anne Quinquenel, Anne Calleja, Romain Guieze, Emmanuelle Ferrant, Annie Brion, Kamel Laribi
Journal: Blood (2019)
Photodynamic Therapy Is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer
Authors: Xinning Wang, Gopolakrishnan Ramamurthy, Aditi A. Shirke, Ethan Walker, Joey Mangadlao, Ziying Wang, Yu Wang, Lingpeng Shan, Mark D. Schluchter, Zhipeng Dong, Susann M. Brady-Kalnay, Natalie K. Walker, Madhusudhana Gargesha, Gregory MacLennan, Dong Luo, Rongcan Sun, Bryan Scott, Debashish Roy, Jing Li, James P. Basilion
Journal: Cancer Research (2019)

Local and metastatic relapses of prostate cancer often occur following attempted curative resection of the primary tumor, and up to 66% of local recurrences are associated with positive margins. Therefore, technologies that can improve the visualization of tumor margins and adjuvant therapies to ablate remaining tumor tissues are needed during surgical resection of prostate adenocarcinoma. Photodynamic agents have the potential to combine both fluorescence for image-guided surgery (IGS) and photodynamic therapy (PDT) to resect and ablate cancer cells. The objective of this study was to determine the utility of a targeted PDT agent for IGS and adjuvant PDT. Using a previously developed prostate-specific membrane antigen (PSMA)-targeted PDT agent, PSMA-1-Pc413, we showed that PSMA-1-Pc413 selectively highlighted PSMA-expressing tumors, allowing IGS and more complete tumor resection compared with white light surgery. Subsequent PDT further reduced tumor recurrence and extended animal survival significantly. This approach also enabled identification of tumor cells in lymph nodes. In summary, this study presents a potential new treatment option for patients with prostate cancer undergoing surgery, which improves tumor visualization and discrimination during surgery, including identification of cancer in lymph nodes. SIGNIFICANCE: These findings present a photodynamic agent that can be used for both photodynamic therapy and image-guided surgery, allowing better visualization of tumor margins and elimination of residual tumor tissues.
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial
Authors: Abhishek Maiti, Courtney D. DiNardo, Caitlin R. Rausch, Jorge E. Cortes, Naveen Pemmaraju, Naval G. Daver, Farhad Ravandi, Guillermo Garcia-Manero, Gautam M. Borthakur, Kiran Naqvi, Maro N. Ohanian, Nicholas J. Short, Yesid Alvarado, Christopher B. Benton, Tapan M. Kadia, Koichi Takahashi, Musa E. Yilmaz, Nitin Jain, Steven M. Kornblau, Koji Sasaki, Michael Andreeff, Prithviraj Bose, Alessandra Ferrajoli, Ghayas C. Issa, Elias Jabbour, Lucia Masarova, Michael E. Rytting, Philip A. Thompson, Sa A Wang, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, Qi Zhang, Antonio Cavazos, Helen Ma, Carol A. Bivins, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, Sherry A. Pierce, Jing Ning, Wei Qiao, John S. Welch, Hagop M. Kantarjian, Marina Y Konopleva
Journal: Blood (2019)
Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial
Authors: Salmon Manier, Meletios A. Dimopoulos, Cyrille Hulin, Xavier Leleu, Michel Delforge, Katja C. Weisel, Ruiyun Jiang, Shankar Srinivasan, Bruno Costa, Suzanne Robinson, Thierry Facon
Journal: Blood (2019)
Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes
Authors: Kensuke Kayamori, Cheng Zhong, Daisuke Shinoda, Shuhei Koide, Motohiko Oshima, Yaeko Nakajima-Takagi, Naoya Mimura, Ryoji Ito, Kaoru Tohyama, William Lennox, Marla Weetall, Josephine Sheedy, Emiko Sakaida, Koutaro Yokote, Atsushi Iwama
Journal: Blood (2019)
Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy
Authors: Krishna R. Juluri, Alexandre V. Hirayama, Erin Mullane, Nancy Cleary, Qian Vicky Wu, David G. Maloney, Cameron J. Turtle, Merav Bar, Jordan Gauthier
Journal: Blood (2019)
Contraceptives and cervical carcinoma.
Authors: A Singer, R P Shearman, G C Scott
Journal: BMJ (1969)

The authors express reservations similar to those expressed by others relating to the recently published rates of carcinoma-in-situ in women using the diaphragm as compared with those using contraceptive oral steroids.  Data from the Planned Parenthood Clinics in New York City compared 3 ethnic groups: white Negro and Puerto Rican.  All were shown to have variations in incidence rates for invasive cervical carcin oma possibly due to such etiological factors as early sexual activity multiparity and low socioeconomic status.  Those using oral contraceptives were 78% of the possibly high risk groups and therefore might be expected to have more cervical carcinoma.  The simulataneous random matching procedure employed may have reduced the differences somewhat.  Larger groups on an international scale and over extended periods of time are needed for study.  It is suggested that the proposed coital mutagen may have gained entry during adolescence or before the use of either a mechanical barrier or oral contraception.
Abstract 15520: Plasma Glycosylceramides as Prognostic Biomarkers in the Acute Myocardial Infarction
Authors: Sock-Hwee Tan, Leonardo Carvalho, Jianhong Ching, Sock Cheng Poh, Chee Tang Chin, Arthur M Richards, Richard Troughton, Alan Yean Yip Fong, Bryan Yan, Aruni Seneviratn, Jean-Paul Kovalik, Scott Summers, Mark Chan
Journal: Circulation (2018)

Introduction: Plasma sphingolipids, particularly ceramides, have emerged as one of several non-cholesterol lipids that predict cardiovascular outcomes. In the early phase of acute myocardial infarc...
Can Structural Grading of Foveal Hypoplasia Predict Future Vision in Infantile Nystagmus?
Authors: Sohaib R. Rufai, Mervyn G. Thomas, Ravi Purohit, Catey Bunce, Helena Lee, Frank A. Proudlock, Irene Gottlob
Journal: Ophthalmology (2019)

To evaluate structural grading and quantitative segmentation of foveal hypoplasia using handheld OCT, versus preferential looking (PL), as predictors of future vision in preverbal children with infantile nystagmus.Longitudinal cohort study.Forty-two patients with infantile nystagmus (19 with albinism, 17 with idiopathic infantile nystagmus, and 6 with achromatopsia) were examined.Spectral-domain handheld OCT was performed in preverbal children up to 36 months of age. Foveal tomograms were graded using our 6-point grading system for foveal hypoplasia and were segmented for quantitative analysis: photoreceptor length, outer segment (OS) length, and foveal developmental index (FDI; a ratio of inner layers versus total foveal thickness). Patients were followed up until they could perform chart visual acuity (VA) testing. Data were analyzed using linear mixed regression models. Visual acuity predicted by foveal grading was compared with prediction by PL, the current gold standard for visual assessment in infants and young children.Grade of foveal hypoplasia, quantitative parameters (photoreceptor length, OS length, FDI), and PL VA were obtained in preverbal children for comparison with future chart VA outcomes.We imaged 81 eyes from 42 patients with infantile nystagmus of mean age 19.8 months (range, 0.9-33.4 months; standard deviation [SD], 9.4 months) at the first handheld OCT scan. Mean follow-up was 44.1 months (range, 18.4-63.2 months; SD, 12.0 months). Structural grading was the strongest predictor of future VA (grading: r = 0.80, F = 67.49, P < 0.0001) compared with quantitative measures (FDI: r = 0.74, F = 28.81, P < 0.001; OS length: r = 0.65; F = 7.94, P < 0.008; photoreceptor length: r = 0.65; F = 7.94, P < 0.008). Preferential looking was inferior to VA prediction by foveal grading (PL: r = 0.42, F = 3.12, P < 0.03).Handheld OCT can predict future VA in infantile nystagmus. Structural grading is a better predictor of future VA than quantitative segmentation and PL testing. Predicting future vision may avert parental anxiety and may optimize childhood development.
Medicaid Policy and Liver Transplant for Alcohol‐Associated Liver Disease
Authors: Brian P. Lee, Eric Vittinghoff, Mark J. Pletcher, Jennifer L. Dodge, Norah A. Terrault
Journal: Hepatology (2019)

Background and Aims In some states, liver transplantation (LT) for alcohol‐associated liver disease (ALD) is covered by Medicaid only with documentation of abstinence and/or alcohol rehabilitation. Different Medicaid policies may affect the distribution of LT for ALD, particularly post‐2011, as centers have adopted early (i.e., specific abstinence period not required) LT practices. Approach and Results We surveyed Medicaid policies in all states actively performing LT and linked state policies to prospectively collected national registry data on LT recipients from 2002 to 2017 with ALD as the primary listing diagnosis. We categorized Medicaid policies for states as “restrictive” (requiring documentation of a specific abstinence period and/or rehabilitation) versus “unrestrictive” (deferring to center eligibility policies). Difference‐of‐differences analysis, comparing 2002‐2011 versus 2012‐2017, evaluated whether restrictive policies were associated with decreased proportion of LTs paid by Medicaid among patients with ALD post‐2011. We performed sensitivity analyses to account for any differences by diagnosis of hepatocellular carcinoma, hepatitis C virus, nonalcoholic steatohepatitis, or Medicare insurance. We also performed a sensitivity analysis to account for any difference by prevalence of ALD among restrictive versus unrestrictive states. Of 10,836 LT recipients in 2002‐2017, 7,091 were from 24 states in the restrictive group and 3,745 from 14 states in the unrestrictive group. The adjusted proportion (95% confidence interval) of LTs paid by Medicaid among restrictive versus unrestrictive states between 2002 and 2011 was 17.6% (15.4%‐19.8%) versus 18.9% (15.4%‐22.3%) ( P = 0.54) and between 2012 and 2017, 17.2% (14.7%‐19.7%) versus 23.2% (19.8%‐26.6%) ( P = 0.005). In difference‐of‐differences analysis, restrictive (versus unrestrictive) policies were associated with a 4.7% (0.8%‐8.6%) ( P = 0.02) absolute lower adjusted proportion of LTs for ALD paid by Medicaid post‐2011. Conclusions Restrictive Medicaid policies are present in most states with active LT centers and are associated with lower proportions of LTs for ALD paid by Medicaid post‐2011 compared to states with unrestrictive Medicaid policies. Reevaluation of Medicaid alcohol use policies may be warranted, to align more closely with contemporary center‐level practices.